$TSLX

Sixth Street Specialty Lending, Inc. Earnings and Revenue – MUN:1T6

Sixth Street Specialty Lending, Inc. (MUN:1T6) reported earnings of 0.36 EUR per share, missing the 0.43 EUR estimate by 14.73%. Revenue for the quarter was 80.84M EUR, below the estimated 89.27M EUR. Analysts project 0.37 EUR in EPS and 83.37M EUR in revenue for the next quarter.

Original reporting
Published May 23, 2026, 1:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 23, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sixth Street Specialty Lending, Inc. Earnings and Revenue – MUN:1T6 — source image
Decision brief

The 30-second read

$TSLXNeutralLow
01

Why it matters

The earnings miss could lead to a temporary dip in the stock price, but projections for the next quarter remain positive.

02

Market read

The news has limited direct impact on TSLX, but may influence sector sentiment.

03

What to watch

Broader economic conditions and interest rate environment could influence sector performance beyond this earnings report.

Relevance 6/10Timing: short-term

Background

Sixth Street Specialty Lending, Inc. reported earnings below analyst estimates, indicating potential short-term weakness.

Company-level read

Ticker impact

$TSLXNeutralMedium confidence
Context

The news pertains to Sixth Street Specialty Lending, Inc., which is not directly associated with TSLX, but the sentiment score indicates a neutral outlook for the related sector.

Expected impact

Minimal to no immediate price movement expected for TSLX.

Evidence & confidence

The earnings report is specific to a different company; TSLX's sentiment remains neutral, and no direct correlation suggests significant price change.

Market effects

Potential slight cautiousness in the specialty lending sector due to earnings miss.

Limited regional impact, as the news pertains to a US-based company.

Minimal, as the company and sector are primarily regional.

Counterpoint

The earnings miss might be an isolated incident; if the company's fundamentals remain strong, long-term investors may view this as a buying opportunity.

Key entities

  • Sixth Street Specialty Lending, Inc.

    A specialty finance company focusing on lending activities.

Related articles

$PRGMed

Q2 Rundown: PROG (NYSE:PRG) Vs Other Specialty Finance Stocks

Encore Capital Group (PRG) reported Q2 revenue of $491.9M, up 11.3% YoY, beating estimates. HASI reported $36.32M, down 64.9% YoY, missing estimates. TSLX reported $97.84M, down 14.9% YoY, beating estimates. MAIN reported $149.6M, up 3.9% YoY, topping estimates. PRG stock is up 10.4%, HASI up 8.1%, TSLX up 3.1%, and MAIN up 2.5% since reporting.

$TSLXMed

Sixth Street Specialty Lending, Inc. Q2 2026 Earnings Call Summary

Sixth Street Specialty Lending, Inc. reported Q2 2026 results on an earnings call, citing stable NAV despite widening credit spreads and sequential repayment activity that added $0.08/share in activity-based fees. Management expects more M&A in H2, guiding annualized ROE of 10% to 10.5% if turnover stays below 20%. The firm issued $300m unsecured notes, extended its revolver to May 2031, and triggered a June 10b5-1 buyback.

$TSLXMed

SECOND QUARTER 2026 EARNINGS RESULTS Sixth Street Specialty Lending, Inc. Reports Second Quarter Results; Declares a Third Quarter Base Dividend Per Share of…

Sixth Street Specialty Lending, Inc. (TSLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 k SECOND QUARTER 2026 EARNINGS RESULTS Sixth Street Specialty Lending, Inc. Reports Second Quarter Results; Declares a Third Quarter Base Dividend Per Share of $0.42 NEW YORK — August 4, 2026 — Sixth Street Specialty Lending, Inc. (NYSE: TSLX, or the “Company”) today

$SLSMedAI 9/10

Sellas Life Sciences phase 3 AML trial reaches key milestone

SELLAS Life Sciences (NASDAQ:SLS) announced its Phase 3 REGAL trial for galinpepimut-S in AML patients reached the 80th event, triggering final analysis. The company plans to release topline results this quarter. Galinpepimut-S targets the WT1 protein and is being evaluated for maintenance therapy in AML. SELLAS also develops SLS009, a CDK9 inhibitor for AML.